

## SUPPLEMENTARY DATA

**Table 1 or Supplementary Table. HOMA quartile for the prediction of CAC incidence and progression in the Multi-Ethnic Study of Atherosclerosis.**

	<b>Model 1</b>	<b>Model 2</b>	<b>Model 3</b>
<b>Incident CAC</b>			
<i>Relative Risk (95% CI)</i>			
▪ HOMA Q1	1 (ref)	1 (ref)	1 (ref)
▪ HOMA Q2	1.24 (0.98 – 1.56)	1.10 (0.87 – 1.41)	1.04 (0.81 – 1.32)
▪ HOMA Q3	<b>1.53 (1.23 – 1.91)**</b>	1.20 (0.94 – 1.54)	1.06 (0.82 – 1.37)
▪ HOMA Q4	<b>1.78 (1.32 – 2.22)**</b>	1.21 (0.92 – 1.61)	1.02 (0.77 – 1.35)
<b>CAC Progression†</b>			
<i>Δ Volume score/year (95% CI)</i>			
▪ HOMA Q1	1 (ref)	1 (ref)	1 (ref)
▪ HOMA Q2	3.9 (-3.3 – 11.0)	-0.7 (-8.2 – 6.7)	3.2 (-3.6 – 10.0)
▪ HOMA Q3	<b>9.0 (1.9 – 16.1)*</b>	-0.3 (-8.2 – 7.6)	5.1 (-2.2 – 12.4)
▪ HOMA Q4	<b>11.5 (4.5 – 18.4)**</b>	-3.0 (-11.8 – 5.8)	5.0 (-3.4 – 13.4)

**HOMA quartiles:** 1<sup>st</sup> quartile (0.14 – 0.79), 2<sup>nd</sup> quartile (0.80 – 1.24), 3<sup>rd</sup> quartile (1.24 – 2.03), 4<sup>th</sup> quartile (>2.03)

**Model 1** = Adjusted for age, gender, race/ethnicity, MESA site, years between CAC scans

**Model 2** = Model 1 + NCEP ATPIII metabolic syndrome components (waist circumference, impaired fasting glucose, low HDL-C, high triglycerides, hypertension [categorical])

**Model 3** = Model 1 + NCEP ATPII metabolic syndrome components (continuous) except for impaired fasting glucose (categorical), diabetes, smoking, LDL-C, family history of CHD, cholesterol-lowering medications

† Additionally adjusted for log (baseline CAC) in the CAC progression model

\* p<0.05

\*\* p<0.005